Introduction
Patients with bone metastases frequently face debilitating pain, functional limitations, and psychosocial challenges that significantly affect daily life. Consequently, precise measurement of health-related quality of life (HRQOL) has become essential for effective oncology care. Chow et al. (2009) developed the EORTC QLQ-BM22 specifically to address this gap. Moreover, the module has accumulated over 160 citations on Google Scholar and consistently demonstrates strong reliability and validity across international populations. Furthermore, researchers and clinicians rely on the EORTC QLQ-BM22 to complement the core EORTC QLQ-C30 questionnaire.
Therefore, this article provides a complete overview of its features, scoring, applications, and practical considerations to help experts integrate the tool seamlessly into studies and patient management.
Key Features of the EORTC QLQ-BM22
Purpose and Use
The primary purpose of the EORTC QLQ-BM22 is to measure health-related quality of life (HRQOL) in cancer patients with bone metastases. Additionally, it captures symptom burden and functional impact with high clinical sensitivity. By using this module alongside the EORTC QLQ-C30, clinicians and researchers obtain a comprehensive picture of pain, daily functioning, and emotional well-being.
Target Population
The EORTC QLQ-BM22 is designed for adult cancer patients aged 18 years and older who have confirmed bone metastases.
Validated age groups include:
- Young adults (18–24 years)
- Middle-aged adults (25–44 years)
- Older adults (45–64 years)
- Seniors (65+ years)
Therefore, the questionnaire is widely applicable across the adult oncology population and is suitable for both clinical practice and research settings.
Structure
The questionnaire contains 22 items divided into four distinct scales. Specifically, these include:
- Painful Sites (5 items): Examines the extent of pain in specific areas such as the back, chest, and limbs.
- Pain Characteristics (3 items): Assesses the nature of the pain, including its constancy and response to medication.
- Functional Interference (8 items): Measures how pain restricts physical activities like walking, sitting, or strenuous tasks.
- Psychosocial Aspects (6 items): Explores emotional concerns, including feelings of isolation and worries about future health.
This structure enables a nuanced profile of each patient’s experience.
Scoring Method
All 22 items use a 4-point Likert scale (1 = Not at all, 4 = Very much) with a recall period of the past week particularly when the module is administered alongside the EORTC QLQ-C30.
Researchers first calculate raw subscale scores as the average of the relevant items. Then, they linearly transform these to a 0–100 scale.
- Higher scores on the Painful Sites, Pain Characteristics, and Psychosocial scales indicate a worse state
- Higher scores on the Functional Interference scale signify better functioning.
Importantly, items 21 and 22 require reversal before scaling.
Administration Format
The EORTC QLQ-BM22 is a self-administered questionnaire, making it easy to implement in various clinical and research settings.
It can be administered using several formats:
- Paper-based questionnaires
- Digital or online surveys
- In-person interviews
- Phone or video call assessments
Importantly, the questionnaire typically requires 5–10 minutes to complete, making it feasible even in busy oncology clinics.
Applications of the EORTC QLQ-BM22
Clinicians and researchers apply the EORTC QLQ-BM22 in multiple ways:
- Monitoring: It allows healthcare teams to track disease progression or the side effects of treatments like radiotherapy.
- Treatment Planning: Data from the questionnaire informs individualized palliative care strategies.
- Research Endpoint: It serves as a validated outcome measure in international clinical trials to compare the efficacy of different interventions.
Consequently, it helps evaluate intervention efficacy and patient-centered outcomes in oncology.
Languages and availability
The EORTC QLQ-BM22 is available in more than 20 languages, including:
- Arabic
- English
- Mandarin Chinese
- Spanish
- French
- German
- Russian
- Portuguese
- Japanese
- Hindi
This broad linguistic coverage facilitates multicultural research and global clinical use.
Reliability and Validity
The EORTC QLQ-BM22 demonstrates high reliability and validity. Cronbach’s alpha values typically range from 0.7 to 0.9 across subscales, indicating excellent internal consistency. Additionally, the module shows strong responsiveness to change, convergent validity with pain measures, and discriminant validity from unrelated constructs.
Validation studies confirm its robustness:
Limitations and Considerations
Despite its strengths, the EORTC QLQ-BM22 has a few limitations:
- Self-report: Respondents may be influenced by social desirability bias or personal interpretation.
- Narrow Focus: The questionnaire is specifically designed for bone metastases and may not capture the full range of symptoms in multi-organ systemic disease.
- Cultural Bias: While translated into over 20 languages, subjective perceptions of pain can still vary across different cultural backgrounds.
- Social Desirability Bias: Patients may answer in a way they believe is expected by their healthcare provider.
Other Versions And Related Questionnaires
Unlike some quality-of-life tools, no shorter form of the QLQ-BM22 currently exists. However, related questionnaires include:
- Functional Assessment of Cancer Therapy – Bone Pain (FACT-BP)
- Bone Metastasis Quality of Life Questionnaire (BOMET-QoL)
While BOMET-QoL is shorter, the QLQ-BM22 provides more detailed insights into pain, function, and psychosocial factors.
Additional Resources
- The original validation study link
- You can access the questionnaire as a PDF through this link
- For inquiries, contact the EORTC Quality of Life Unit
- For the official Scoring Manual, consult this link
Frequently Asked Questions (FAQ)
- Who can use the EORTC QLQ-BM22?
Clinicians, researchers, and healthcare providers use this tool for adult cancer patients (18+) who have confirmed bone metastases. - How long does it take to complete the questionnaire?
Patients typically take 5 to 10 minutes to complete the 22 items, making it highly practical for busy clinics. - How is the QLQ-BM22 administered?
It offers significant flexibility and can be administered via paper-based forms, digital platforms, or through in-person and phone interviews. - Is there any cost to using the QLQ-BM22?
The tool is free for academic and non-profit use, though it requires a formal license from the EORTC Quality of Life Group.
A Word From ResRef about the EORTC QLQ-BM22
The EORTC QLQ-BM22 is a robust, clinician-validated tool for capturing the unique quality-of-life challenges of patients with bone metastases. By providing a detailed look at pain and function, it enables more targeted interventions, ultimately enhancing outcomes and improving the quality of life for individuals navigating advanced cancer challenges.
References
- Chow, E., Hird, A., Velikova, G., Johnson, C., Dewolf, L., Bezjak, A., Wu, J., Shafiq, J., Sezer, O., Kardamakis, D., van der Linden, Y., Ma, B., Castro, M., Arnalot, P. F., Ahmedzai, S., Clemons, M., Hoskin, P., Yee, A., Brundage, M., & Bottomley, A. (2009). The European Organisation for Research and Treatment of Cancer quality of life questionnaire for patients with bone metastases: The EORTC QLQ-BM22. European Journal of Cancer, 45(7), 1146–1152. link
- Chow, E., Nguyen, J., Zhang, L., Tseng, L.-M., Hou, M.-F., Fairchild, A., Vassiliou, V., Jesus-Garcia, R., Alm El-Din, M. A., Kumar, A., Forges, F., Chie, W.-C., & Bottomley, A. (2012). International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer, 118(5), 1457–1465. link
- Raman, S., Ding, K., Chow, E., Meyer, R. M., Nabid, A., Chabot, P., Coulombe, G., Ahmed, S., Kuk, J., Dar, A. R., Mahmud, A., Fairchild, A., Wilson, C. F., Wu, J. S. Y., Dennis, K., DeAngelis, C., Wong, R. K. S., Zhu, L., & Brundage, M. (2016). A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. Radiotherapy and Oncology, 119(2), 208–212. link
